Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [57]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 293
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Dipeptidyl peptidase IV, a kidney brush-border serine peptidase
Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., & Young, A. R. (1976) · Biochemical Journal · doi:10.1042/bj1570169 · Cited by 254
Cited by
Items 101–200 of 798
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
“However, increasing evidence indicates that some of these metabolites have biological activity that may contribute to the pleiotropic effects of GLP-1 independently of the GLP-1 receptor [27, 28].”
BackgroundGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationGlucagon-like peptide-1, glucose homeostasis and diabetes
Holst, J. J., Deacon, C. F., Vilsbøll, T., Krarup, T., & Madsbad, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.01.003 · Cited by 163
Self-citationPharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1
Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K., & Young, A. (2001) · Drug Development Research · doi:10.1002/ddr.1195 · Cited by 158
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Self-citationTherapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155
Self-citationPauly, R. P., Rosche, F., Wermann, M., McIntosh, C. H. S., Pederson, R. A., & Demuth, H.-U. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23222 · Cited by 155
Green, B. D., Hand, K. V., Dougan, J. E., McDonnell, B. M., Cassidy, R. S., & Grieve, D. J. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.08.001 · Cited by 151
Feinglos, M. N., Saad, M. F., Pi‐Sunyer, F. X., An, B., Santiago, O., & on behalf of the Liraglutide Dose‐Response Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01567.x · Cited by 151
Vallöf, D., Maccioni, P., Colombo, G., Mandrapa, M., Jörnulf, J. W., Egecioglu, E., Engel, J. A., & Jerlhag, E. (2016) · Addiction Biology · doi:10.1111/adb.12295 · Cited by 150
“and extensively (Deacon et al. 1995), the clinically available GLP-1 receptor agonist, liraglutide, has protracted”
BackgroundHansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P. N., & Holst, J. J. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.6.e1010 · Cited by 148
Self-citationFrom the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
Self-citationDeacon, C., Wamberg, S., Bie, P., Hughes, T., & Holst, J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 145
“…of DPP IV in GLP-1 metabolism formed the basis for the suggestion that DPP IV inhibition may be a novel method for treating diabetic hyperglycaemia (Deacon et al. 1995b, Holst & Deacon 1998), since inhibiting the enzyme would be likely to protect GLP-1 from degradation and, therefore, improve its…”
BackgroundMethodInfluentialSelf-citationDeacon, C. F., Danielsen, P., Klarskov, L., Olesen, M., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 145
“for NH2-terminal degradation of GLP-1 in plasma (4,18).”
BackgroundSelf-citationNeumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 161
Hui, H., Farilla, L., Merkel, P., & Perfetti, R. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460863 · Cited by 143
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 158
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 141
“The kidneys also play a role in the clearance of GLP-1 from the circulation [3,9,10].”
BackgroundHe, H., Tran, P., Yin, H., Smith, H. T., Batard, Y., Wang, L., Einolf, H. J., Gu, H., Mangold, J. B., Fischer, V., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023010 · Cited by 160
“Dipeptidyl peptidase 4 (DPP-4, DPP-IV) is a highly specialized aminopeptidase that is present in plasma, the kidney, and the intestinal brush-border membranes, as well as on the surface of capillary endothelial cells, hepatocytes, and a subset of T lymphocytes (Deacon et al., 1995; Mentlein, 1999).”
BackgroundTolessa, T., Gutniak, M., Holst, J. J., Efendic, S., & Hellström, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci942 · Cited by 139
“In the fed state, GLP-1 (20–40 pmol kg 2 1 min 2 1 ) reduced motility, an inhibition unaffected by L-NNA, whereas motility was stimulated by exendin(9-39)amide.”
BackgroundMethodInfluentialSelf-citationNutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X., Wu, M., & Qi, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.009 · Cited by 150
“Another issue is the shorter alf-life of GLP-1, only several minutes in blood plasma Deacon et al., 1995), which seriously limits its application n clinical practice.”
BackgroundChoi, S., Baudyš, M., & Kim, S. W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026435.27086.94 · Cited by 150
“(e-mail: rburns@ pharm.utah.edu) ABBREVIATIONS: DPP-IV, dipeptidyl peptidase IV; GLP-1, glucagon-like peptide-1.”
BackgroundMethodCirculating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2
Brubaker, P. L. (1997) · Endocrinology · doi:10.1210/en.138.11.4837 · Cited by 136
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 153
Hüttner, S., Graefe-Mody, E. U., Withopf, B., Ring, A., & Dugi, K. A. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008323753 · Cited by 139
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
Basalay, M. V., Mastitskaya, S., Mrochek, A., Ackland, G. L., del Arroyo, A. G., Sanchez, J., Sjoquist, P.-O., Pernow, J., Gourine, A. V., & Gourine, A. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw216 · Cited by 132
Microbial regulation of GLP-1 and L-cell biology
Greiner, T. U., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.012 · Cited by 131
“Based on these facts, it is conceivable that GLP-1 may have different functions depending on where it is secreted and the fact that the peptide has a half-life of only 2 min [11,62], which suggests that GLP-1 may mainly have paracrine rather than hormonal functions, or even signal directly to GLP-1R expressed on vagal…”
BackgroundHolst, J. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00157-5 · Cited by 147
Self-citationHolz, G., & Chepurny, O. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456648 · Cited by 131
Is GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130
“GLP-1 is cleaved from proglucagon in specific intestinal enterocytes called L cells, and secreted primarily as an amidated 30amino acid peptide GLP-1(7-36)NH2 (1,17).”
BackgroundInfluentialBalks, H. J., Holst, J. J., von zur Mühlen, A., & Brabant, G. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3816 · Cited by 130
“One of these methods, the deconvolution technique DESADE, is based on the plasma half-life of the hormone, whichweestimatedfromtheoriginaltimeseries.Theplasma half-life of GLP-1 may vary with the specificity of the antibody used, but as all three techniques independently revealed a comparable frequency of GLP-1 pulses…”
MethodResultSelf-citationGlucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives
Meier, J. J., Gallwitz, B., Schmidt, W. E., & Nauck, M. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01434-6 · Cited by 147
Luginbuhl, K. M., Schaal, J. L., Umstead, B. R., Mastria, E. M., Li, X., Banskota, S., Arnold, S., Feinglos, M. N., D’Alessio, D. A., & Chilkoti, A. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0078 · Cited by 130
“Unfortunately, GLP1’s clinical utility is limited by its short two minute half-life 16 , owing to its small size, rapid clearance by renal filtration, and inactivation by the ubiquitous, cell surface exopeptidase, DPP-IV 17 .”
InfluentialGLP-1 and cardioprotection: from bench to bedside
Ravassa, S., Zudaire, A., & Diez, J. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs123 · Cited by 126
“The glucagon-like peptide-1 [GLP-1 (7-36) amide] is a hormone”
BackgroundInfluentialPhysiology of Incretins in Health and Disease
Deacon, C. F., & Ahrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 126
“Furthermore, DPP-4 inhibition, which leads to increased levels of endogenous intact (active) GLP-1 and GIP, is associated with lower total incretin levels, in both animals [57] and humans [34], suggesting that their secretion has been suppressed.”
BackgroundInfluentialSelf-citationClinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
He, Y. (2012) · Clinical Pharmacokinetics · doi:10.2165/11598080-000000000-00000 · Cited by 143
“Both endogenous and exogenous GLP-1 are rapidly inactivated by DPP-4, and more than 80% of the entire GLP-1 pool in the blood circulation consists of inactive GLP-1.”
BackgroundInfluentialKeane, F. M., Nadvi, N. A., Yao, T., & Gorrell, M. D. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08051.x · Cited by 124
Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes
Menge, B. A., Schrader, H., Ritter, P. R., Ellrichmann, M., Uhl, W. H., Schmidt, W. E., & Meier, J. J. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.08.001 · Cited by 128
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
“Despite their antidiabetic potential, both GLP-1 and GIP undergo enzymatic degradation by dipeptidylpeptidase-IV (DPP-IV) and rapid removal from the circulation [7-9].”
BackgroundThe mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Exenatide Versus Glibenclamide in Patients with Diabetes
Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125
Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124
“Inhibiting DDP-IV prevents GLP-1 degradation in the porcine ileum by 46% at baseline (16, 17).”
Tolessa, T., Gutniak, M., Holst, J. J., Efendić, S., & Hellström, P. M. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026678925120 · Cited by 131
“like peptide-I (7-37) co-encoded in the glucagon gene is a”
BackgroundMethodSelf-citationD'Alessio, D. A., Vogel, R., Prigeon, R., Laschansky, E., Koerker, D., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 122
“To determine the overall effect of GLP-1 on glucose disposition after a meal we studied a group of healthy, conscious baboons before and after intragastric glucose administration during infusions of saline, and two treatments to eliminate the action of GLP-1: ( a ) exendin-[9-39] (Ex-9), a peptide receptor antagonist…”
BackgroundMethodInfluentialIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 119
Novel Dipeptidyl Peptidase-4–Inhibiting Peptide Derived From β-Lactoglobulin
Uchida, M., Ohshiba, Y., & Mogami, O. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11089sc · Cited by 136
DPP-4 Inhibition and the Path to Clinical Proof
Åhrén, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00376 · Cited by 138
Tavares, W., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.1.e134 · Cited by 118
“Indeed, the half-life for GLP, glucagon-like peptide; GIP, glucose-dependent insulinotropic polypeptide; GHRH, growth hormone-releasing hormone; DP, dipeptidyl peptidase, GLP-1, GLP-1-(7—36)NH2; GLP-2, GLP-2-(1—33).”
BackgroundInfluentialDeacon, C. F., & Holst, J. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.011 · Cited by 126
Self-citationGreen, B. D., Irwin, N., Duffy, N. A., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.043 · Cited by 121
“While DPP IV is the primary culprit for GLP-1 inactivation, it is a ubiquitous enzyme responsible for the inactivation of numerous regulatory peptides, including GIP and pituitary adenylate cyclase-activating polypeptide (PACAP) (Deacon et al., 1995; Mentlein, 1999).”
BackgroundMentlein, R. (2004) · International Review of Cytology · doi:10.1016/s0074-7696(04)35004-7 · Cited by 115
“Several studies in vitro and in vivo have shown that GLP-1 is primarily degraded at the N-terminus by the action of DPP IV resulting in biologically inactive des(His-Ala)-GLP-1 (Deacon et al., 1995a (Deacon et al., ,b, 1998a KieVer et al., 1995; Mentlein et al., 1993b) .”
BackgroundGLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113
“Following food ingestion, GLP-1 appears in the plasma within minutes and due to its rapid degradation by dipeptidyl peptidase-4 (DPP-4), is undetectable by 3 h [5–7].”
BackgroundThe glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122
Derosa, G., Maffioli, P., SALVADEO, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.10.007 · Cited by 120
Hansen, L. (1999) · Endocrinology · doi:10.1210/en.140.11.5356 · Cited by 111
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
Xiao, Q., Boushey, R. P., Cino, M., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.4.r1057 · Cited by 111
“Indeed, much of the available literature assessing circulating levels of GLP-1 is difficult to interpret because of the use of antisera that did not discriminate between bioactive GLP-1-(7—36) amide and the inactive degradation product GLP-1-(9—36) amide (7, 19).”
BackgroundPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 111
“The incretin hormones GLP-1 and gastric inhibitory peptide (GIP) are secreted by enteroendocrine cells in response to postprandial hyperglycemia and account for 60–70% of postprandial insulin secretion (the incretin effect).”
BackgroundInfluentialGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Association of Type 2 Diabetes Candidate Polymorphisms in KCNQ1 With Incretin and Insulin Secretion
Müssig, K., Staiger, H., Machicao, F., Kirchhoff, K., Guthoff, M., Schäfer, S. A., Kantartzis, K., Silbernagel, G., Stefan, N., Holst, J. J., et al. (2009) · Diabetes · doi:10.2337/db08-1589 · Cited by 109
“GLP-1 and gastric inhibitory polypeptide (GIP) immunoreactivitiy were determined using radioimmunoassays specific for the COOH-terminal of the peptides (21,22).”
MethodSelf-citationBak, M. J., Wewer Albrechtsen, N. J., Pedersen, J., Knop, F. K., Vilsbøll, T., Jørgensen, N. B., Hartmann, B., Deacon, C. F., Dragsted, L. O., & Holst, J. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12352 · Cited by 108
Self-citation18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma
Kiesewetter, D. O., Gao, H., Ma, Y., Niu, G., Quan, Q., Guo, N., & Chen, X. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1980-0 · Cited by 107
“Consequently, the native peptide is rapidly degraded by dipeptidyl-peptidase-IV via cleavage of two N-terminal residues, which abolishes the agonistic effects at GLP-1R [4].”
Åhrén, B., & Hughes, T. E. (2004) · Endocrinology · doi:10.1210/en.2004-1174 · Cited by 111
Nagell, C. F., Wettergren, A., Pedersen, J. F., Mortensen, D., & Holst, J. J. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410004424 · Cited by 108
“meal (18, 30), they may actually turn out to result in a similar inhibition.”
BackgroundSelf-citationSchiellerup, S. P., Skov‐Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00075 · Cited by 117
“As for GIP andGLP-2, GLP-1 is degraded by the enzymeDPP-4 (97), which cleaves it after its alanine in position 2, giving it a half-life <2min (61, 71, 97–99).”
Self-citationAntidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Meneses, M. J., Silva, B. M., Sousa, M., Sá, R., Oliveira, P. F., & Alves, M. G. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710145753 · Cited by 132
“Still, GLP-1 is rapidly degraded and inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) [104].”
BackgroundThe Incretin Approach for Diabetes Treatment
Holst, J. J., & Ørskov, C. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s197 · Cited by 106
“GLP-1 is metabolized extremely rapidly by the ubiquitous enzyme DPP IV, which cleaves off two amino acid residues from the NH2-terminus and renders the metabolite [designated GLP-1 (9-36)amide] inactive (43).”
BackgroundSelf-citationReview article: a comparison of glucagon‐like peptides 1 and 2
Janssen, P., Rotondo, A., Mulé, F., & Tack, J. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12092 · Cited by 105
“76 It circulates in two equally potent forms, GLP-1(7-36 amide) and GLP-1(7-37), although the amidated form is more abundant after eating.”
BackgroundInfluentialKoole, C., Wootten, D. L., Simms, J., Valant, C., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072884 · Cited by 113
Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104
“This procedure has previously been shown to prevent in vitro degradation of incretin hormones in human plasma samples (4, 18).”
BackgroundSelf-citationCai, H.-Y., Hölscher, C., Yue, X.-H., Zhang, S., Wang, X.-H., Qiao, F., Yang, W., & Qi, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.022 · Cited by 107
“The half-life of GLP-1 in blood plasma is only several minutes (Deacon et al., 1995), which seriously limits the application of GLP-1 in clinical practice.”
Metabolic surgery and gut hormones – A review of bariatric entero-humoral modulation
Ashrafian, H., & le Roux, C. W. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.03.012 · Cited by 114
Arulmozhiraja, S., Matsuo, N., Ishitsubo, E., Okazaki, S., Shimano, H., & Tokiwa, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166275 · Cited by 105
Marty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., & Spigelman, I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.599646 · Cited by 102
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“Native GLP1 has an intravenous half-life of 2 min, which is largely mediated through its degradation by DPP4 and its rapid renal elimination 68,69 .”
Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6364 · Cited by 110
Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.155 · Cited by 103
Self-citationHe, Y., Serra, D. B., Wang, Y., Campestrini, J., Rivière, G., Deacon, C. F., Holst, J. J., Schwartz, S. L., Nielsen, J. C., & Ligueros‐Saylan, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746070-00003 · Cited by 109
Self-citationSaxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0014-9 · Cited by 113
Deacon, C. F., Plamboeck, A., Møller, S., & Holst, J. J. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00452.2001 · Cited by 103
Self-citationPauly, R. P., Demuth, H., Rosche, F., Schmidt, J., White, H. A., Lynn, F. C., McIntosh, C. H. S., & Pederson, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90090-2 · Cited by 102
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Stephens, S. B., Schisler, J. C., Hohmeier, H. E., An, J., Sun, A. Y., Pitt, G. S., & Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.011 · Cited by 89
“Identification of the DPP-4-catalyzed cleavage event proved to be amajor milestone in the development of methods for detecting active forms of GLP-1, and for development of new analogs that are resistant to enzymatic cleavage (Deacon et al., 1995; Kieffer et al., 1995).”
Iwamoto, Y., Taniguchi, T., Nonaka, K., Okamoto, T., Okuyama, K., Ferreira, J. C. A., & Amatruda, J. M. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-272 · Cited by 115
“Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA (2006) Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.”
BackgroundInfluentialIs glucagon-like peptide 1 an incretin hormone?
Nauck, M. A. (1999) · Diabetologia · doi:10.1007/s001250051165 · Cited by 112
“celerated in the presence of exendin [9-39]) and does not easily support an incretin role for GLP-1.”
BackgroundRask, E., Olsson, T., Söderberg, S., Holst, J. J., Tura, A., Pacini, G., & Åhrén, B. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.011 · Cited by 104
Self-citationGLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide
Elahi, D., Egan, J. M., Shannon, R. P., Meneilly, G. S., Khatri, A., Habener, J. F., & Andersen, D. K. (2008) · Obesity · doi:10.1038/oby.2008.229 · Cited by 101
“Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.”
BackgroundInfluentialIwamoto, Y., Tajima, N., Kadowaki, T., Nonaka, K., Taniguchi, T., Nishii, M., Ferreira, J. C. A., & Amatruda, J. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01197.x · Cited by 104
“Through these mechanisms, DPP-4 inhibitors improve control of postprandial glucose excursions and lower fasting plasma glucose (FPG) in patients with type 2 diabetes [3,4].”
BackgroundWang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99
Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet
Gutniak, M. K., Larsson, H., Heiber, S. J., Juneskans, O. T., Holst, J. J., & Ahrén, B. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.843 · Cited by 99
“The active layer consisted of 400 jbtg (119 nmol) of human synthetic GLP-I(7-36) amide (Saxon Biochemicals, Hannover, Germany), Klucel, mannitol, sodium taurocholate (enhancer), magnesium stearate, and Spralene mint flavor.”
BackgroundMethodSelf-citationNagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., Yoshikawa, S., Asano, O., & Tanaka, I. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4999 · Cited by 101
Novikoff, A., O'Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 95
Mochida, T., Hira, T., & Hara, H. (2010) · Endocrinology · doi:10.1210/en.2009-1510 · Cited by 107
“In addition, tripeptides such as diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) have been shown to block DPP-IV-mediated GLP-1 degradation in vitro (34, 35) as competitive substrates (36).”
BackgroundGlucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse
Jerlhag, E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.005 · Cited by 93
Krieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
“Fos expression is also detected in the PBN after DPP-IV inhibition [75] or IP CCK [63], an effect attenuated by vagal disruption.”
InfluentialHansen, A. M. K., Bödvarsdóttir, T., Nordestgaard, D. N. E., Heller, R. S., Gotfredsen, C. F., Maedler, K., Fels, J. J., Holst, J. J., & Karlsen, A. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2080-1 · Cited by 89
“... as a result of processing by PC 2, leaving the active form of the GLP-1 peptide trapped in a larger fragment, the major proglucagon fragment [8, 9]. After GLP- 1 is released from the intestinal L-cells to the circulation, it is very rapidly degraded to an inactive metabolite (GLP-1 [9– 37]) by the enzyme dipeptidy…”
BackgroundSelf-citation
Metadata
- Authors
- Deacon, C. F., Johnsen, A. H., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-03
- Volume
- 80
- Issue
- 3
- Pages
- 952-957
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068183831
- Cited by
- 792
- References
- 28
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 24 · 2023: 10 · 2022: 14 · 2021: 24 · 2020: 18 · 2019: 34 · 2018: 25 · 2017: 37 · 2016: 41 · 2015: 22 · 2014: 27 · 2013: 40 · 2012: 42
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- glucagon-like peptide-1, dipeptidyl peptidase IV, human plasma, peptide metabolism, endogenous metabolites
- MeSH terms
- Chromatography, High Pressure Liquid, Female, Glucagon, Humans, Male, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.